Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.

Higa N, Pelz A, Birch D, Beck IA, Sils T, Samson P, Bwakura-Dangarembizi M, Bolton-Moore C, Capparelli E, Chadwick E, Frenkel LM.

J Pediatric Infect Dis Soc. 2019 Jun 13. pii: piz038. doi: 10.1093/jpids/piz038. [Epub ahead of print]

PMID:
31194860
2.

Correlates of HIV detection among breastfeeding postpartum Kenyan women eligible under Option B.

Chan M, Muriuki EM, Emery S, Kanthula R, Chohan V, Frenkel LM, Wald A, Chohan B, Overbaugh J, Roxby AC.

PLoS One. 2019 May 31;14(5):e0216252. doi: 10.1371/journal.pone.0216252. eCollection 2019.

3.

Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission.

Williams-Wietzikoski CA, Campbell MS, Payant R, Lam A, Zhao H, Huang H, Wald A, Stevens W, Gray G, Farquhar C, Rees H, Celum C, Mullins JI, Lingappa JR, Frenkel LM.

J Virol. 2019 Jun 14;93(13). pii: e01769-18. doi: 10.1128/JVI.01769-18. Print 2019 Jul 1.

PMID:
30996101
4.

Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.

Milne RS, Silverman RA, Beck IA, Mckernan-Mullin J, Deng W, Sibley TR, Dross S, Kiarie JN, Sakr SR, Coombs RW, Chung MH, Frenkel LM.

AIDS. 2019 May 1;33(6):941-951. doi: 10.1097/QAD.0000000000002134.

PMID:
30946148
5.

Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Bull ME, McKernan JL, Styrchak S, Kraft K, Hitti J, Cohn SE, Tapia K, Deng W, Holte S, Mullins JI, Coombs RW, Frenkel LM.

AIDS Res Hum Retroviruses. 2019 Jun;35(6):557-566. doi: 10.1089/AID.2018.0211. Epub 2019 Apr 30.

PMID:
30892052
6.

Minority and majority pre-treatment HIV-1 drug resistance associated with failure of 1st-line NNRTI ART in Kenyan women.

Milne RS, Silverman RA, Beck IA, Mckernan-Mullin J, Deng W, Sibley TR, Dross S, Kiarie JN, Sakr SR, Coombs RW, Chung MH, Frenkel LM.

AIDS. 2019 Jan 16. doi: 10.1097/QAD.0000000000002134. [Epub ahead of print]

PMID:
30664004
7.

Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.

Soria J, Mugruza R, Levine M, León SR, Arévalo J, Ticona E, Beck IA, Frenkel LM.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):150-154. doi: 10.1089/AID.2018.0239. Epub 2019 Jan 22.

PMID:
30560685
8.

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA; IMPAACT 1066 study team.

Lancet HIV. 2018 Dec;5(12):e715-e722. doi: 10.1016/S2352-3018(18)30257-1.

9.

The Clinical Implications of Pretreatment Drug Resistance-A Moving Target.

Shafer RW, Frenkel LM.

Clin Infect Dis. 2019 Jul 2;69(2):215-217. doi: 10.1093/cid/ciy895. No abstract available.

PMID:
30321316
10.

Implementation of a point mutation assay for HIV drug resistance testing in Kenya.

Duarte HA, Beck IA, Levine M, Kiptinness C, Kingoo JM, Chohan B, Sakr SR, Chung MH, Frenkel LM.

AIDS. 2018 Oct 23;32(16):2301-2308. doi: 10.1097/QAD.0000000000001934.

PMID:
30005020
11.

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.

Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, McKernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, Ticona E, Frenkel LM.

AIDS. 2018 Jul 17;32(11):1389-1401. doi: 10.1097/QAD.0000000000001824.

12.

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.

Stekler JD, Milne R, Payant R, Beck I, Herbeck J, Maust B, Deng W, Tapia K, Holte S, Maenza J, Stevens CE, Mullins JI, Collier AC, Frenkel LM.

PLoS Med. 2018 Mar 27;15(3):e1002537. doi: 10.1371/journal.pmed.1002537. eCollection 2018 Mar.

13.

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa.

Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, Kidoguchi L, Donnell D, Mugo NR, Bukusi EA, Katabira E, Asiimwe S, Morton J, Morrison S, Haugen H, Mujugira A, Haberer JE, Ware NC, Wyatt MA, Marzinke MA, Frenkel LM, Celum C, Baeten JM; Partners Demonstration Project Team.

Gates Open Res. 2017 Nov 6;1:3. doi: 10.12688/gatesopenres.12752.1.

14.

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.

Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S.

Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5. Erratum in: Lancet Infect Dis. 2017 Dec 15;:.

15.

Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.

Silverman RA, Beck IA, Kiptinness C, Levine M, Milne R, McGrath CJ, Bii S, Richardson BA, John-Stewart G, Chohan B, Sakr SR, Kiarie JN, Frenkel LM, Chung MH.

J Infect Dis. 2017 Dec 19;216(12):1569-1578. doi: 10.1093/infdis/jix544.

16.

Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.

Duarte HA, Panpradist N, Beck IA, Lutz B, Lai J, Kanthula RM, Kantor R, Tripathi A, Saravanan S, MacLeod IJ, Chung MH, Zhang G, Yang C, Frenkel LM.

J Infect Dis. 2017 Dec 1;216(suppl_9):S824-S828. doi: 10.1093/infdis/jix413. Review.

17.

Genetic analyses of HIV env associated with uveitis in antiretroviral-naive individuals.

Williams-Wietzikoski CA, So ID, Bull ME, Samleerat T, Pathanapitoon K, Kunavisarut P, Kongyai N, Ngo-Giang-Huong N, Frenkel LM, Sirirungsi W.

AIDS. 2017 Aug 24;31(13):1825-1830. doi: 10.1097/QAD.0000000000001550.

18.

Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.

Mullins JI, Frenkel LM.

J Infect Dis. 2017 Mar 15;215(suppl_3):S119-S127. doi: 10.1093/infdis/jiw636. Review.

19.

Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.

Kanthula R, Rossouw TM, Feucht UD, van Dyk G, Beck IA, Silverman R, Olson S, Salyer C, Cassol S, Frenkel LM.

AIDS. 2017 May 15;31(8):1143-1148. doi: 10.1097/QAD.0000000000001446.

20.

H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir.

Wagner TA, Huang HC, Salyer CE, Richardson KM, Weinberg A, Nachman S, Frenkel LM.

AIDS Res Ther. 2017 Feb 13;14(1):7. doi: 10.1186/s12981-017-0135-1.

21.

HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection.

Goldman JD, Frenkel LM, Mullins JI.

JAMA. 2016 Nov 15;316(19):2044-2045. doi: 10.1001/jama.2016.16030. No abstract available.

PMID:
27838715
22.

Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.

Chung MH, Silverman R, Beck IA, Yatich N, Dross S, McKernan-Mullin J, Bii S, Tapia K, Stern J, Chohan B, Sakr SR, Kiarie JN, Frenkel LM.

AIDS. 2016 Jun 19;30(10):1680-2. doi: 10.1097/QAD.0000000000001110.

23.

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.

Beck IA, Payant R, Ngo-Giang-Huong N, Khamduang W, Laomanit L, Jourdain G, Frenkel LM.

J Virol Methods. 2016 Jul;233:51-5. doi: 10.1016/j.jviromet.2016.03.014. Epub 2016 Mar 26.

24.

Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation.

Panpradist N, Beck IA, Chung MH, Kiarie JN, Frenkel LM, Lutz BR.

PLoS One. 2016 Jan 11;11(1):e0145962. doi: 10.1371/journal.pone.0145962. eCollection 2016.

25.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

26.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

27.

Short Communication: Analysis of Minor Populations of Human Immunodeficiency Virus by Primer Identification and Insertion-Deletion and Carry Forward Correction Pipelines.

Hughes P, Deng W, Olson SC, Coombs RW, Chung MH, Frenkel LM.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):296-302. doi: 10.1089/AID.2015.0202. Epub 2015 Dec 15.

28.

Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.

Ticona E, Bull ME, Soria J, Tapia K, Legard J, Styrchak SM, Williams C, Mitchell C, La Rosa A, Rosa AL, Coombs RW, Frenkel LM.

AIDS. 2015 Aug 24;29(13):1617-22. doi: 10.1097/QAD.0000000000000758. Erratum in: AIDS. 2015 Sep 24;29(15):2065. Rosa, Alberto L A [corrected to La Rosa, Alberto].

29.

Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.

Olson SC, Ngo-Giang-Huong N, Beck I, Deng W, Britto P, Shapiro DE, Bumgarner RE, Mullins JI, Van Dyke RB, Jourdain G, Frenkel LM.

AIDS. 2015 Jul 31;29(12):1467-71. doi: 10.1097/QAD.0000000000000737.

30.

Ethics of HIV research in children.

Rossouw TM, Crane J, Frenkel LM.

Lancet Infect Dis. 2015 Jun;15(6):634-5. doi: 10.1016/S1473-3099(15)00023-7. Epub 2015 May 17. No abstract available.

31.

Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.

Heffron R, Mugo N, Were E, Kiarie J, Bukusi EA, Mujugira A, Frenkel LM, Donnell D, Ronald A, Celum C, Baeten JM; Partners PrEP Study Team.

AIDS. 2014 Nov 28;28(18):2771-6. doi: 10.1097/QAD.0000000000000493.

32.

Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

van Zyl GU, Frenkel LM, Chung MH, Preiser W, Mellors JW, Nachega JB.

AIDS. 2014 Nov 28;28(18):2643-8. doi: 10.1097/QAD.0000000000000502. No abstract available.

33.

Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.

Dross SE, Rossi SS, Beck IA, Micek MA, Blanco AJ, Seidel KD, Montoya P, Capparelli EV, Frenkel LM.

AIDS. 2014 Oct 23;28(16):2491-3. doi: 10.1097/QAD.0000000000000451. No abstract available.

34.

Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.

Mutsvangwa J, Beck IA, Gwanzura L, Manhanzva MT, Stranix-Chibanda L, Chipato T, Frenkel LM.

J Virol Methods. 2014 Dec 15;210:36-9. doi: 10.1016/j.jviromet.2014.09.005. Epub 2014 Sep 17.

35.

Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.

Chung MH, Beck IA, Dross S, Tapia K, Kiarie JN, Richardson BA, Overbaugh J, Sakr SR, John-Stewart GC, Frenkel LM.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):246-53. doi: 10.1097/QAI.0000000000000312.

36.

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.

Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM.

Science. 2014 Aug 1;345(6196):570-3. doi: 10.1126/science.1256304. Epub 2014 Jul 10.

37.

Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.

Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, Maenza J, Stevens CE, Buskin SE, Mullins JI, Frenkel LM, Collier AC.

Antivir Ther. 2015;20(1):77-80. doi: 10.3851/IMP2780. Epub 2014 May 15.

38.

Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.

Beck IA, Deng W, Payant R, Hall R, Bumgarner RE, Mullins JI, Frenkel LM.

J Clin Microbiol. 2014 Jul;52(7):2320-7. doi: 10.1128/JCM.00306-14. Epub 2014 Apr 16.

39.

Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs.

Mitchell C, Dross S, Beck IA, Micek MA, Frenkel LM.

Clin Infect Dis. 2014 Apr;58(8):1190-3. doi: 10.1093/cid/ciu068. Epub 2014 Feb 5.

40.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21.

41.

Improved detection of rare HIV-1 variants using 454 pyrosequencing.

Larsen BB, Chen L, Maust BS, Kim M, Zhao H, Deng W, Westfall D, Beck I, Frenkel LM, Mullins JI.

PLoS One. 2013 Oct 2;8(10):e76502. doi: 10.1371/journal.pone.0076502. eCollection 2013.

42.

Nevirapine-Resistant HIV-1 DNA in Breast Milk After Single-Dose Nevirapine With or Without Zidovudine for Prevention of Mother-to-Child Transmission.

Gantt S, Payant R, Carlsson J, Micek MA, Blanco AJ, Beck IA, Matunha L, Montoya P, Matediana E, Gloyd S, Frenkel LM.

J Pediatric Infect Dis Soc. 2012 Sep;1(3):244-9. doi: 10.1093/jpids/pis065. Epub 2012 Jul 3.

43.

Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay.

Ellis GM, Vlaskin TA, Koth A, Vaz LE, Dross SE, Beck IA, Frenkel LM.

J Virol Methods. 2013 Sep;192(1-2):39-43. doi: 10.1016/j.jviromet.2011.11.030. Epub 2013 May 6.

44.

Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

McLaughlin S, Swenson LC, Hu S, Hughes P, Harrigan PR, Coombs RW, Frenkel LM.

AIDS Res Hum Retroviruses. 2013 May;29(5):814-25. doi: 10.1089/AID.2012.0024. Epub 2013 Mar 6.

45.

Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time.

Bull ME, Heath LM, McKernan-Mullin JL, Kraft KM, Acevedo L, Hitti JE, Cohn SE, Tapia KA, Holte SE, Dragavon JA, Coombs RW, Mullins JI, Frenkel LM.

J Infect Dis. 2013 Apr 15;207(8):1206-15. doi: 10.1093/infdis/jit016. Epub 2013 Jan 11.

46.

An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells.

Wagner TA, McKernan JL, Tobin NH, Tapia KA, Mullins JI, Frenkel LM.

J Virol. 2013 Feb;87(3):1770-8. doi: 10.1128/JVI.01985-12. Epub 2012 Nov 21.

47.

Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry.

Wagner TA, Lin CH, Tobin NH, Côté HC, Sloan DD, Jerome KR, Frenkel LM.

Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):55-8. doi: 10.1002/cyto.b.21045. Epub 2012 Oct 8.

48.

Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women.

Mitchell C, Balkus JE, Fredricks D, Liu C, McKernan-Mullin J, Frenkel LM, Mwachari C, Luque A, Cohn SE, Cohen CR, Coombs R, Hitti J.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):13-9. doi: 10.1089/AID.2012.0187. Epub 2012 Nov 5.

49.

Associations between genital tract infections, genital tract inflammation, and cervical cytobrush HIV-1 DNA in US versus Kenyan women.

Mitchell C, Balkus JE, McKernan-Mullin J, Cohn SE, Luque AE, Mwachari C, Cohen CR, Coombs R, Frenkel LM, Hitti J.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):143-8. doi: 10.1097/QAI.0b013e318274577d.

50.

Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.

Micek MA, Blanco AJ, Carlsson J, Beck IA, Dross S, Matunha L, Seidel K, Montoya P, Gantt S, Matediana E, Jamisse L, Gloyd S, Frenkel LM.

J Infect Dis. 2012 Jun 15;205(12):1811-5. doi: 10.1093/infdis/jis282. Epub 2012 Apr 5.

Supplemental Content

Loading ...
Support Center